Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.61 |
| ▸ | ULK1 | O75385 | 7/20 | 0.59 |
| ▸ | CCNK | O75909 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CCND3 | P30281 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.56 |
| ▸ | PLK1 | P53350 | 1/20 | 0.55 |
| ▸ | BCL6 | P41182 | 2/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19654276 | 0.90 | ULK1 (0.60) | BRD4ULK1CCNA2CDK2PLK1 | |
| SCHEMBL17547455 | 0.89 | ULK1 (0.60) | ULK1CCNA2CDK2PLK1KIF11 | |
| SCHEMBL17547584 | 0.88 | ULK1 (0.61) | ULK1BCL6SYKPTK2INSR | |
| SCHEMBL17544643 | 0.87 | ULK1 (0.78) | ULK1PTK2 | |
| SCHEMBL1474254 | 0.83 | BCL6 (0.56) | BRD4ULK1BCL6SYKPTK2 | |
| SCHEMBL1474255 | 0.83 | BCL6 (0.57) | BRD4ULK1CCNA2CDK2CCND3 | |
| SCHEMBL16208517 | 0.82 | KIF11 (0.72) | KIF11PKM | |
| SCHEMBL17544617 | 0.82 | BRD4 (0.72) | BRD4CCNKCCNA2CDK2CCND3 | |
| SCHEMBL29575097 | 0.82 | BRD4 (0.72) | BRD4CCNKCCNA2CDK2CCND3 | |
| SCHEMBL17547484 | 0.81 | ULK1 (0.58) | ULK1SYKPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021163633-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-05-23 | — | — | US | disclosed |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-05-23 | — | — | US | disclosed |
| US-10266549-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266549-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3185868-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | BRD4 1044/4885ULK1 1/4885CCNK 327/4885 |
| US-10266549-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | BRD4 1044/4885ULK1 1/4885CCNK 327/4885 |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | ULK1, ULK2, ULK3 | BRD4 510/4885ULK1 1/4885CCNK 211/4885 |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | BRD4 1036/4885ULK1 1/4885CCNK 463/4885 |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | BRD4 1036/4885ULK1 1/4885CCNK 463/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | BRD4 1044/4885ULK1 1/4885CCNK 327/4885 |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | BRD4 1036/4885ULK1 1/4885CCNK 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.